Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2r)-2-amino-3-phenylpropyl Carbamate
2. (r)-2-amino-3-phenylpropylcarbamate Hydrochloride
3. Adx-n05
4. Benzenepropanol, Beta-amino-, Carbamate (ester), (betar)-
5. Jzp-110
6. Solriamfetol
7. Sunosi
1. Jzp-110 Hydrochloride
2. 178429-65-7
3. Solriamfetol (hydrochloride)
4. K7ro88sp7a
5. Solriamfetol Hydrochloride [usan]
6. Solriamfetol Hydrochloride (usan)
7. R-228060
8. Sunosi (tn)
9. Unii-k7ro88sp7a
10. Adx-n05 Hydrochloride
11. Ykp-10a Hydrochloride
12. Schembl8430382
13. Adx-n-05 Hydrochloride
14. Skl-n-05 Hydrochloride
15. Chembl4297212
16. Dtxsid101027927
17. R-228060 Hydrochloride
18. Hy-109043a
19. Solriamfetol Hydrochloride [mi]
20. Solriamfetol Hydrochloride [who-dd]
21. Cs-0112102
22. O-carbamoyl-(d)-phenylalaninol Hydrochloride
23. D11328
24. Solriamfetol Hydrochloride [orange Book]
25. (d)-o-carbamoylphenylalaninol Hydrochloride Salt
26. R228060;jzp-110;adx-n05;skl-n05;ykp-10
27. (2r)-2-amino-3-phenylpropyl Carbamate, Monohydrochloride
28. (betar)-beta-amino-benzenepropanol 1-carbamate Hydrochloride (1:1)
29. (r)-(+)-2-amino-1-carbamoyloxy-3-phenylpropane Hydrochloride
30. Benzenepropanol, .beta.-amino-, 1-carbamate, Hydrochloride (1:1), (.beta.r)-
31. 561069-23-6
Molecular Weight | 230.69 g/mol |
---|---|
Molecular Formula | C10H15ClN2O2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 230.0822054 g/mol |
Monoisotopic Mass | 230.0822054 g/mol |
Topological Polar Surface Area | 78.3 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 179 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).
Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).
N06BA14
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?